Royal Bank of Canada increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 19.8% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 61,316 shares of the biotechnology company’s stock after purchasing an additional 10,120 shares during the period. Royal Bank of Canada’s holdings in Arrowhead Pharmaceuticals were worth $3,844,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. Tsfg LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at $29,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. WPG Advisers LLC lifted its holdings in Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 471 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. HC Wainwright upped their price objective on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Leerink Partners raised their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th. B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Chardan Capital upped their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.33.
Arrowhead Pharmaceuticals Stock Performance
NASDAQ:ARWR opened at $86.64 on Friday. The stock has a 50 day simple moving average of $81.37 and a 200 day simple moving average of $72.15. The stock has a market cap of $12.20 billion, a P/E ratio of -38.51 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $18.73 and a 1-year high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business’s quarterly revenue was up 171.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) earnings per share. Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
Featured Articles
- Five stocks we like better than Arrowhead Pharmaceuticals
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
